LPL and coronary artery disorder: LPL activity is increased by apolipoprotein A‐V (APOA5), but reduced by apolipoprotein C‐III (APOC3) and angiopoietin‐like 4 (ANGPTL4), all of which have been associated with CAD in a genome‐wide significant fashion (Table 3).